English Archives - Page 4 of 11 - Lipum AB (publ) Press Releases

Lipum advances SOL‑116 into phase 2 and carries out a rights issue of up to approximately SEK 187 million at a subscription price of SEK 6.70 per share

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS. SEE ALSO THE SECTION "IMPORTANT INFORMATION" [...]

templtokenlogin2024-05-06T09:04:28+02:00

Lipum to participate in following upcoming

templtokenlogin2024-03-21T10:14:36+01:00

Lipum reports positive interim results from clinical phase 1 study showing that SOL-116 reduces plasma BSSL levels in healthy subjects

Lipum AB (publ) announces that the first part of the clinical phase 1 study, where healthy subjects received a single dose of the drug candidate SOL-116, has been completed with positive results. These confirm an expected pharmacokinetic profile, consistently good safety profile and that SOL-116 interacts with its target protein BSSL (bile salt-stimulated lipase). The [...]

templtokenlogin2024-03-21T10:14:36+01:00

Lipum has been granted funding from Vinnova for an Eurostars application

Lipum AB (publ), which has developed the biological drug candidate SOL-116 for treatment of chronic inflammatory diseases such as rheumatoid arthritis, announced today that they have been awarded a grant of SEK 300,000 from Sweden's innovation agency Vinnova. The grant will be used to prepare an application for Eurostars. Eurostars is the largest international funding [...]

templtokenlogin2024-03-21T10:14:36+01:00

Lipum AB announces the Nomination Committee for the 2024 Annual General Meeting

Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2024. In accordance with the decision at the Annual General Meeting, the three largest shareholders in terms of voting rights on 1 September 2023 have appointed a Nomination Committee for the Annual General Meeting 2024. Pursuant to the resolution of the Annual [...]

templtokenlogin2024-03-21T10:14:36+01:00

Ola Sandborgh takes office as CEO for Lipum AB today

Lipum AB (publ) is strengthening its leadership when going into phase II by appointing Ola Sandborgh as its new CEO where he takes over the helm from Einar Pontén. Ola has more than three decades of experience from the pharmaceutical industry where he has worked in leading roles in different commercial, innovation and business development [...]

2024-03-21T10:14:36+01:00

Lipum changes its liquidity provider to Carnegie Investment Bank AB

Lipum AB (publ) has terminated the liquidity provider assignment with Erik Penser Bank AB and has appointed Carnegie Investment Bank AB as new liquidity provider for the company's shares on Nasdaq Stockholm. The arrangement is in accordance with the framework of Nasdaq Stockholm's rules on liquidity providers. In the role of liquidity provider Carnegie undertakes [...]

2024-03-21T10:14:36+01:00

Lipum appoints Ola Sandborgh as new Chief Executive Officer

Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced that the Board of Directors has appointed Ola Sandborgh as new Chief Executive Officer, effective from 1 December 2023. Ola Sandborgh has more than three decades of experience from the pharmaceutical industry where he has worked in leading roles in different [...]

2024-03-21T10:14:36+01:00

Lipum AB – interim report for the period July-September 2023

Lipum AB (publ) has published the interim report for period July to September for 2023. Below is a summary, a complete report (only in Swedish) is available on the company's website. CEO Einar Pontén comments: “The multiple dosing of healthy subjects in our ongoing Phase 1 clinical trial was started according to plan.”Financial summary January [...]

2024-03-21T10:14:36+01:00

Lipum to participate in following upcoming

Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming events. BioStock Investor Meeting, 20 September, Stockholm, SwedenRedeye theme: Autoimmune and Inflammatory Disease, 3 October, Stockholm, SwedenSmåbolagsdagen i Lund, Aktiespararna, 9 October, Lund, SwedenBIO-Europe, 6–8 November, München, GermanyUmeå på börsen, 14 November, Umeå, SwedenRedeye Life [...]

2024-03-21T10:14:36+01:00

Third Party Embeds

Tracking Cookies

Privacy Policy

Contact Information